1100 related articles for article (PubMed ID: 32843053)
1. The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy.
Liu D; Badeti S; Dotti G; Jiang JG; Wang H; Dermody J; Soteropoulos P; Streck D; Birge RB; Liu C
Cell Commun Signal; 2020 Aug; 18(1):134. PubMed ID: 32843053
[TBL] [Abstract][Full Text] [Related]
2. In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes.
Naghizadeh A; Tsao WC; Hyun Cho J; Xu H; Mohamed M; Li D; Xiong W; Metaxas D; Ramos CA; Liu D
PLoS Comput Biol; 2022 Mar; 18(3):e1009883. PubMed ID: 35303007
[TBL] [Abstract][Full Text] [Related]
3. Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells.
Xiong W; Chen Y; Kang X; Chen Z; Zheng P; Hsu YH; Jang JH; Qin L; Liu H; Dotti G; Liu D
Mol Ther; 2018 Apr; 26(4):963-975. PubMed ID: 29503199
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.
Liu D; Tian S; Zhang K; Xiong W; Lubaki NM; Chen Z; Han W
Protein Cell; 2017 Dec; 8(12):861-877. PubMed ID: 28488245
[TBL] [Abstract][Full Text] [Related]
5. Methods of Machine Learning-Based Chimeric Antigen Receptor Immunological Synapse Quality Quantification.
Gan J; Cho JH; Lee R; Naghizadeh A; Poon LY; Wang E; Hui Z; Liu D
Methods Mol Biol; 2023; 2654():493-502. PubMed ID: 37106203
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
Qu J; Mei Q; Chen L; Zhou J
Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
[TBL] [Abstract][Full Text] [Related]
7. Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs).
Cassioli C; Patrussi L; Valitutti S; Baldari CT
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430728
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
Inthagard J; Edwards J; Roseweir AK
Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
[TBL] [Abstract][Full Text] [Related]
10. Ganglioside-Functionalized Nanoparticles for Chimeric Antigen Receptor T-Cell Activation at the Immunological Synapse.
Zang H; Siddiqui M; Gummuluru S; Wong WW; Reinhard BM
ACS Nano; 2022 Nov; 16(11):18408-18420. PubMed ID: 36282488
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance.
Zhang Q; Lu W; Liang CL; Chen Y; Liu H; Qiu F; Dai Z
Front Immunol; 2018; 9():2359. PubMed ID: 30369931
[TBL] [Abstract][Full Text] [Related]
12. Standardized protocol for the evaluation of chimeric antigen receptor (CAR)-modified cell immunological synapse quality using the glass-supported planar lipid bilayer.
Cho JH; Tsao WC; Naghizadeh A; Liu D
Methods Cell Biol; 2023; 173():155-171. PubMed ID: 36653082
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
[TBL] [Abstract][Full Text] [Related]
14. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
15. Imaging CAR-T Synapse as a Quality Control for CAR Engineering.
Xiao Q; Su X
Methods Mol Biol; 2023; 2654():503-512. PubMed ID: 37106204
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T-cell immunotherapy in breast cancer: development and challenges.
Toulouie S; Johanning G; Shi Y
J Cancer; 2021; 12(4):1212-1219. PubMed ID: 33442419
[TBL] [Abstract][Full Text] [Related]
17. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
[TBL] [Abstract][Full Text] [Related]
18. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
Sloas C; Gill S; Klichinsky M
Front Immunol; 2021; 12():783305. PubMed ID: 34899748
[TBL] [Abstract][Full Text] [Related]
19. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment?
Sadeqi Nezhad M; Seifalian A; Bagheri N; Yaghoubi S; Karimi MH; Adbollahpour-Alitappeh M
Front Immunol; 2020; 11():603237. PubMed ID: 33324420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
